Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The company is hoping longer follow-up will deliver enough positive trial data on its CRISPR T-cell therapies for blood ...

ERS Genomics provides essential and foundational licenses to its Nobel prize winning CRISPR/Cas9 technology to companies integrating it into their commercial programs. With a portfolio of 100 ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations. It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct ...

In October, CRISPR Therapeutics co-founder Emmanuelle Charpentier and Intellia co-founder Jennifer Doudna shared the 2020 Nobel Prize in Chemistry for their work on CRISP/Cas9.

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. Read on to ...

The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially ...